Published on 26 Mar 2024 on Zacks via Yahoo Finance

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

Axsome Therapeutics AXSM announced encouraging data from the phase III SYMPHONY study on its investigational narcolepsy drug AXS-12. The study achieved its primary endpoint of a rapid and significant reduction in weekly cataplexy events.

Data from the study showed that treatment with AXS-12 reduced cataplexy attacks by 83% over five weeks compared with 66% for placebo. In fact, treatment with AXS-12 rapidly reduced weekly cataplexy attacks, as it achieved a reduction of 56% in the first week compared to 31% for placebo.

Treatment with AXS-12 also induced an increase in remission of cataplexy (100% reduction from baseline) and increased cataplexy-free days (days with zero cataplexy attacks). Per management, 33% of patients who received AXS-12 achieved remission of cataplexy compared to 9.5% of placebo patients. Treatment with the therapy increased the percentage of cataplexy-free days to 84%, compared to 22% for placebo.